Day: September 2, 2022

INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des marchés financiers (AMF)Date of settlementof information Total number of shares Number of shares without voting rights (*) Number of voting rights for threshold calculation (**) Number of actual voting rights (exercisable at shareholders’ meeting)August 31, 2022 20 455 403 83 843 23 050 522 22 966 679July 31, 2022 20 455 403 82 029 23 050 622 22 968 593July 2, 2022 (***) 20 455 403 78 771 23 050 722 22 971 951June 30, 2022 22 421 332 2 044 700 25 016 651 22 971 951May 31, 2022 22 421 332 2 042 132 25 018 983 22 976 851April 30, 2022 22 421 332 2 028 732 25 033 983 23 005 251March 31, 2022 22 421 332 1 915 712 24 894...

Modification of the composition of EDF Board of Directors The Board of Directors of EDF, which met on 31 August 2022, took note of the resignation of Mr. François Delattre, a director appointed on the proposal of the State pursuant to Article 6.II of the Order n°2014-948 of 20 August 2014, following his appointment as Ambassador of France to Germany. The Board of Directors thanks him for his contribution to the work of the Board and for his support of the EDF Group’s projects and activities in his capacity as Secretary General of the Ministry of Europe and Foreign Affairs. Mr Delattre had been a director of EDF since June 2019. Biographies of all Board members can be found at:https://www.edf.fr/en/the-edf-group/edf-at-a-glance/governance/board-of-directors This press release is certified. Check its authenticity on medias.edf.com...

TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S. reimbursement update for Transurethral Ultrasound Ablation (“TULSA”), performed with its TULSA-PRO® system. Further to the Company’s press release of August 4, 2022, the Current Procedural Terminology (“CPT®”) Category 1 application for TULSA has been withdrawn for consideration at the upcoming September 2022 CPT® Editorial Panel Meeting. Profound anticipates that an updated application, which will include 2022 utilization data, will be submitted at the appropriate time in 2023. In the meantime, U.S. hospitals performing the TULSA procedure on Medicare...

Orion Corporation NOTIFICATION02.09.2022 at 18:30 ORION CORPORATION: ACQUISITION OF OWN SHARES 02.09.2022Date 02.09.2022  Exchange transaction Buy  Share class ORNBV  Amount 13,947  Average price/share 44,6397 EURHighest price/share 45.0400 EURLowest price/share 44.3300 EURTotal price 622,589.90   EUR     The shares held by Orion Corporation on 02.09.2022:  ORNBV 558,257  On behalf of Orion Corporation Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Janne Tiihonen For more information, please contact: Olli Huotari, SVP, Corporate Functions, Orion Corporation tel. +358 10 426 3054Attachment...

Ålandsbanken Abp  Changes in company’s own shares02.09.2022 at 18:30 EET   Ålandsbanken Abp: Acquisitions of own shares 02.09.2022Date 02.09.2022  ExchangeBourse trade   Nasdaq Helsinki Oy (XHEL)Buy  Share class ALBBV  Amount             174  Average price/share 30.2000 EURHighest price/share 30.2000 EURLowest price/share 30.2000 EURTotal price 5,254.80 EUR     The shares held by Ålandsbanken Abp on 02.09.2022:    ALBBV                  34,052  On behalf of Ålandsbanken Abp Skandinaviska Enskilda Banken AB (Publ)   Antti Salakka                      Janne Tiihonen     For more information, please contact: Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel +358 40 512 7505AttachmentALBBV SBB 02092022

French public limited company (société anonyme) with a share capital of €1,493,903,847.50 Registered office : 1973, boulevard de la Défense 92000 Nanterre – France 552 037 806 RCS Nanterre www.vinci.com   DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 31 AUGUST 2022    Total number of shares 597,561,539Theoretical number of voting rights (including treasury stock) 597,561,539Number of voting rights (excluding treasury stock) 564,718,749  This disclosure is on VINCI web site www.vinci.com (section investors/financial information/regulatory information/7. monthly information concerning the total number of voting rights and shares that make up the company’s capital).Attachment2022 08 31 ddv English version

REGULATED INFORMATION                Paris, 2 September 2022 5:45 PM YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Disclosure of Share Capital and Voting Rights Disclosure of Share Capital and Voting Rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. Register name of the issuer: TOUAX SCA (Euronext Paris: TOUP)Date Total shares outstanding Total voting rights Total exercisable voting rights*August 31, 2022 7,011,547   8,350,162     8,264,345  * excluding rights attached to shares held in treasury **************** TOUAX Group leases out tangible assets (freight railcars, river barges and containers) on a daily basis throughout the world, for its own account and on behalf of third party investors. With...

Company also retains B2i Digital to enhance engagement with the investor community New York, NY, and Tel Aviv, ISRAEL, Sept. 02, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a brand ambassador agreement with Kingcarlx, an American influencer with over 7.4 million followers across all platforms (5.8 million on TikTok, 1 million on Instagram and 600,000 on YouTube), for the Company’s majority-owned 3CL Pharma Ltd. subsidiary’s Tollovid™ 3CL protease inhibitor immune support dietary supplement brand. Together with Kingcarlx, the Company is launching the #TolloUp marketing campaign. Kingcarlx will be focused on promoting the lifestyle aspects of the Tollovid brand focused on encouraging...

Vancouver, B.C., Sept. 02, 2022 (GLOBE NEWSWIRE) — Rugby Resources Ltd. (“Rugby” or the “Company”) (TSX-V: RUG) announces that it has granted an aggregate of 750,000 stock options to 3 employees and consultants and 425,000 stock options to a director with an exercise price of $0.13, exercisable for five years. All options granted are subject to vesting provisions. The Company has also amended the exercise price of an aggregate of 750,000 stock options held by non-insiders with a price of $0.22 to $0.13. Both the grant and amendment of stock options are subject to exchange approval. Additionally, Rugby announces that it has granted 1,151,000 restricted share units (the “RSUs”) to a director and an officer of the Company. The RSUs are subject to vesting provisions and will vest over a period of three years. The RSUs are...